631 reports of this reaction
2.5% of all EPOETIN ALFA reports
#3 most reported adverse reaction
DYSPNOEA is the #3 most commonly reported adverse reaction for EPOETIN ALFA, manufactured by Amgen, Inc. There are 631 FDA adverse event reports linking EPOETIN ALFA to DYSPNOEA. This represents approximately 2.5% of all 25,704 adverse event reports for this drug.
Patients taking EPOETIN ALFA who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for EPOETIN ALFA, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for EPOETIN ALFA:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 631 FDA reports for EPOETIN ALFA. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 2.5% of all adverse event reports for EPOETIN ALFA, making it one of the most commonly reported side effect.
If you experience dyspnoea while taking EPOETIN ALFA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.